Here are 1-3 brief analogies for Tyra Biosciences (TYRA):

• An early-stage Genentech, but focused on designing new drugs to outsmart cancer's resistance to treatment.
• Like Vertex Pharmaceuticals, but applying precision drug design to develop therapies that defeat drug-resistant cancers.
• A specialized, early-stage R&D unit, similar to a focused division within Eli Lilly or Amgen, solely dedicated to creating drugs that overcome cancer's resistance mechanisms.

• TYRA-300: A lead product candidate, this is a selective inhibitor of fibroblast growth factor receptor (FGFR)3 for treating muscle invasive bladder cancer.
• FGFR2-targeting programs: Development programs aimed at intrahepatic cholangiocarcinoma.
• FGFR3-targeting programs (for achondroplasia): Development programs focused on treating achondroplasia.
• REarranged during transfection (RET) kinase-targeting programs: Development programs targeting cancers related to REarranged during transfection kinase.
• FGFR4-targeting programs: Development programs focused on FGFR4-related cancers.
• SNAP platform: A proprietary platform that enables rapid structural design through iterative molecular snapshots.

Tyra Biosciences (TYRA) is a preclinical-stage biopharmaceutical company focused on the research and development of therapies. Its product candidates, such as TYRA-300, are currently in early development and have not yet been commercialized or approved for sale. Therefore, Tyra Biosciences does not currently have major customers, as it is not selling products to other companies (e.g., distributors, hospitals, or other pharmaceutical companies) or directly to individuals (patients).

Todd Harris, Chief Executive Officer

Todd Harris co-founded Tyra Biosciences in August 2018 and has served as its CEO since November 2018. Prior to co-founding Tyra, he co-founded Sienna Biopharmaceuticals, Inc. (SNNA), a clinical-stage biopharmaceutical company, where he was Chief Executive Officer and a board member. Sienna Biopharmaceuticals later filed for Chapter 11 in September 2019 and ceased operations in December 2019. Mr. Harris began his career as a consultant at McKinsey & Company in the Health Care Practice Division. He also serves on the board of directors of Primmune Therapeutics, Inc.

Alan Fuhrman, Chief Financial Officer

Alan Fuhrman joined Tyra Biosciences as Chief Financial Officer in January 2023. He is a veteran leader and board member in the biotechnology industry, with a track record of guiding companies through strategic transactions, including mergers and acquisitions. Mr. Fuhrman has held CFO positions at several companies, including Amplyx Pharmaceuticals (2017–2020), Mirna Therapeutics (2015–2017), and Ambit Biosciences (2010–2014). At Ambit Biosciences, he played a role in leading the company through its initial public offering and oversaw financial operations until its sale to Daiichi Sankyo in January 2015. He also served as interim President, CEO, and board member of Checkmate Pharmaceuticals, Inc. from October 2021 through February 2022, remaining on the board until its acquisition by Regeneron in May 2022. Additionally, he served on the board of directors and as Chair of the Audit Committee for Loxo Oncology from January 2015 until its sale to Eli Lilly in February 2019. Earlier in his career, he practiced as a certified public accountant with Coopers & Lybrand. He currently serves on the board of directors of SpringWorks Therapeutics and Esperion Therapeutics.

Daniel Bensen, Chief Operating Officer

Daniel Bensen is a co-founder of Tyra Biosciences and serves as its Chief Operating Officer. He was also a co-founder and Chief Scientific Officer.

Robert L. Hudkins, Chief Technology Officer

Robert Hudkins joined Tyra Biosciences in January 2020 as Chief Technology Officer, bringing over 30 years of drug discovery experience, including drug design and computational chemistry. He previously spent the majority of his career with Cephalon, Inc. and later with Teva Pharmaceuticals, where he was a Distinguished Scientist and Senior Research Fellow/Senior Research Director in Medicinal Chemistry.

Doug Warner, Chief Medical Officer

Doug Warner was appointed Chief Medical Officer in September 2024, bringing extensive clinical development experience from his 18-year tenure at Amgen.

1. Clinical Trial Failure and Regulatory Approval Risk: As a clinical-stage biopharmaceutical company, Tyra Biosciences' success is primarily dependent on its drug candidates, particularly TYRA-300 (dabogratinib), successfully navigating and completing clinical trials and ultimately gaining regulatory approval. The drug development process is characterized by a high rate of failure, and negative or unexpected results from ongoing or future clinical trials could significantly diminish the company's valuation or lead to the discontinuation of development programs. Tyra Biosciences is currently conducting Phase 2 trials for TYRA-300 in multiple indications, with interim results for some programs anticipated in 2026. Any delays in these trials, unfavorable outcomes, or failure to meet primary endpoints would pose a critical threat to the business.
2. Funding and Capital Needs (Cash Burn and Dilution Risk): Developing and bringing new drugs to market is an expensive and time-intensive endeavor. Tyra Biosciences is currently a loss-making company with substantial research and development (R&D) expenses. While the company reported a cash, cash equivalents, and marketable securities balance of $256.0 million as of Q4 2025, which is projected to fund operations through at least 2027, Tyra Biosciences will require continuous capital raises as it does not yet generate product revenue. Future financing rounds, which are likely necessary to sustain its extensive pipeline and clinical activities, could result in the issuance of new shares, leading to dilution for existing shareholders.
3. Competition Risk: Tyra Biosciences operates within a highly competitive pharmaceutical and biotechnology industry. Various other companies are engaged in developing therapies for similar oncology indications or targeting Fibroblast Growth Factor Receptor (FGFR) biology. While TYRA-300 is positioned as a potential first-in-class, selective FGFR3 inhibitor aiming to offer improved safety and efficacy compared to existing pan-FGFR inhibitors, the emergence of new, more effective, or more affordable therapies from competitors could disrupt Tyra Biosciences' potential market share and commercial viability.

Tyra Biosciences, Inc. is focused on developing therapies for various cancer indications and achondroplasia. The addressable markets for their main product candidates are as follows:

• TYRA-300 for muscle-invasive bladder cancer (FGFR3 inhibitor): The global muscle-invasive bladder cancer therapeutics market was valued at approximately US$ 1.2 billion in 2024 and is projected to reach around US$ 3.655.4 million by 2032. Another estimate places the global muscle invasive bladder cancer treatment market size at USD 4.5 billion in 2023, with a projection to reach USD 7.2 billion by 2032. In the U.S., the market generated revenue of US$ 382.05 million in 2024.
• Programs targeting FGFR2- intrahepatic cholangiocarcinoma: The global intrahepatic cholangiocarcinoma market is estimated at USD 1.7 billion in 2024 and is projected to expand to USD 2.9 billion by 2030. The U.S. intrahepatic cholangiocarcinoma market is expected to grow from approximately USD 0.51 billion in 2024 to about USD 0.83 billion by 2030. In terms of disease type, FGFR2 mutated intrahepatic cholangiocarcinoma is expected to hold a 52.8% share of the intrahepatic cholangiocarcinoma market in 2025.
• Programs targeting FGFR3-related achondroplasia: The global market size for achondroplasia in 2024 is estimated to be around USD 300 million and is expected to reach approximately USD 1.5 billion by 2034. North America represents the largest market, holding approximately 60% of the global market share for achondroplasia treatments.
• Programs targeting REarranged during transfection (RET) kinase: The global RET inhibitor drug market size was valued at USD 1.04 billion in 2025 and is projected to reach USD 4.09 billion by 2033. North America held the largest revenue share of 45.7% in the RET inhibitor drug market in 2025.
• Programs targeting FGFR4-related cancers: The Fibroblast Growth Factor Receptor 4 (FGFR4) market is projected for significant growth, though a specific valuation for the overall market size was not explicitly provided in the search results. However, the broader global Fibroblast Growth Factor Receptor (FGFR) inhibitor market, which includes FGFR4, is expected to reach USD 185.8 million in 2025 and may grow to USD 614.4 million by 2035.

For Tyra Biosciences, Inc. (TYRA), a clinical-stage biopharmaceutical company, the expected drivers of future revenue growth over the next 2-3 years will primarily stem from the progression of its pipeline and the strategic opportunities that arise from successful clinical development, rather than immediate product sales.

Here are 3-5 expected drivers of future revenue growth:

1. Successful Advancement of Dabogratinib (TYRA-300) Through Phase 2 Clinical Trials: The lead product candidate, dabogratinib (TYRA-300), an oral FGFR3-selective inhibitor, is currently being evaluated in Phase 2 clinical studies for multiple indications. Key upcoming milestones include interim Phase 2 data readouts for SURF302 (intermediate-risk non-muscle invasive bladder cancer) by the end of the first half of 2026 and for BEACH301 (achondroplasia) in the second half of 2026. Positive results from these trials would significantly validate the drug's potential, thereby increasing its value and attractiveness for future commercialization or partnerships, which could involve milestone payments or licensing deals. The company's "dabogratinib 3x3" strategy specifically targets these as "potential blockbuster indications."
2. Initiation and Progression of Additional Phase 2 Studies for Dabogratinib: Tyra Biosciences is actively expanding the clinical development of dabogratinib into new, high-value indications. An example of this is the dosing of the first patient in the SURF303 study for low-grade upper tract urothelial carcinoma (LG-UTUC) in 2026. Successful progression in additional indications broadens the market potential of dabogratinib, further enhancing its overall value and increasing opportunities for future revenue generation through partnerships or eventual market entry.
3. Formation of Strategic Partnerships and Licensing Agreements: As a clinical-stage biotechnology company, a significant source of future revenue growth is expected to come from collaborations and licensing agreements with larger pharmaceutical companies. These partnerships can provide non-dilutive funding in the form of upfront payments, milestone payments tied to clinical and regulatory achievements, and potential royalties on future product sales. Tyra Biosciences has stated its commitment to forging strategic partnerships to accelerate the delivery of its therapies. The company's ongoing participation in investor conferences also suggests active engagement with potential partners.
4. Progression of Other Pipeline Assets: Beyond TYRA-300, Tyra Biosciences is also developing other investigational compounds, such as TYRA-200 (an FGFR1/2/3 inhibitor for metastatic intrahepatic cholangiocarcinoma) and TYRA-430 (an FGFR4/3-biased inhibitor for FGF19+/FGR4-driven cancers). The continued advancement of these additional pipeline assets through early clinical stages can contribute to the company's overall valuation and attract further investment or partnerships, indirectly driving future revenue growth.

Share Issuance

• Tyra Biosciences agreed to issue and sell 4,000,000 shares of common stock in March 2026, expecting $126 million in gross proceeds from a block transaction under an "at-the-market" offering program.
• In February 2024, the company completed a private placement financing (PIPE) of approximately $200 million, selling about 15.4 million shares of common stock or pre-funded warrants.
• In September 2021, Tyra Biosciences priced its initial public offering (IPO) of 10,800,000 shares at $16.00 per share, anticipating $172.8 million in gross proceeds.

Inbound Investments

• Tyra Biosciences secured approximately $200 million through a private placement financing in February 2024, led by RA Capital Management and including other institutional investors.
• In March 2021, the company closed a $106 million Series B financing round, led by Nextech Invest with participation from several new and existing investors.
• The company completed its initial public offering in September 2021, raising gross proceeds of $172.8 million.

Capital Expenditures

• Research and development (R&D) expenses for the full year 2025 increased to $102.9 million, up from $80.1 million in 2024.
• These R&D expenditures in 2025 were primarily focused on advancing clinical activities for dabogratinib, including ongoing BEACH301 and SURF302 trials, start-up costs for SURF303, and development for SURF431.
• As of December 31, 2025, the company held $256.0 million in cash, cash equivalents, and marketable securities, which are expected to fund operations through at least 2027, primarily supporting planned clinical programs.